NASDAQ:PGEN Stock Quote
Precigen Inc is a biotechnology company focused on developing innovative gene and cell therapies aimed at addressing a range of diseases, including cancer and genetic disorders
The company leverages its proprietary technologies to create advanced therapeutic solutions that aim to enhance the body's immune response and provide targeted treatment options. By utilizing its expertise in genetic engineering and immunology, Precigen works to bring transformative health solutions to patients while advancing the field of precision medicine.
Frequently Asked Questions
Does Precigen engage in research collaborations?
Yes, Precigen actively engages in research collaborations with academic institutions, hospitals, and other research organizations. These collaborations enhance its scientific capabilities, drive innovation, and enable faster translation of research discoveries into clinical applications.
How can investors learn more about Precigen?
Investors can learn more about Precigen by visiting the company’s official website, which offers detailed information about its products, pipeline, and corporate governance. Additionally, they can access press releases, financial reports, and investor presentations to stay informed.
How does Precigen approach cancer treatment?
Precigen approaches cancer treatment by utilizing innovative gene and cell therapy techniques that harness the power of the immune system to recognize and destroy cancer cells. This includes the development of engineered T-cell therapies that are designed to enhance the body’s natural ability to combat tumors.
How does Precigen ensure safety in its therapies?
Precigen prioritizes safety in its research and development processes by conducting extensive preclinical studies and following rigorous clinical trial protocols. The company adheres to strict regulatory guidelines to ensure that its therapies are both safe and effective for patients.
How is Precigen funded?
Precigen is funded through a combination of public market investments, partnerships, and collaborations. As a publicly traded company, it has access to capital through equity and debt financing, aimed at supporting its research initiatives and clinical trials.
Is Precigen publicly traded?
Yes, Precigen, Inc. is publicly traded on the Nasdaq under the ticker symbol PGEN. Being a publicly traded company provides access to capital markets, which supports the funding of its ongoing research and development efforts.
What are some of Precigen's clinical programs?
Precigen has several clinical programs in its pipeline, including therapies for various types of cancer, such as prostate cancer, ovarian cancer, and other solid tumors. The company is also exploring genetic therapies for rare genetic disorders and aims to bring innovative solutions to market.
What are the future prospects for Precigen?
The future prospects for Precigen are promising, with a strong pipeline of innovative therapies in development and continued advancements in gene and cell therapy technology. As the company progresses through clinical trials and regulatory approvals, it aims to expand its impact in the biotechnology sector and improve patient outcomes.
What are the main challenges Precigen faces?
Like many biotech companies, Precigen faces challenges such as regulatory hurdles, funding limitations, and competition within the rapidly evolving biotechnology sector. Additionally, demonstrating the clinical efficacy and safety of new therapies is critical to gaining regulatory approval and market acceptance.
What does Precigen, Inc. do?
Precigen, Inc. is a biotechnology company focused on developing transformative gene and cell therapies to address unmet medical needs. The company leverages its proprietary UltraPorator technology to deliver genetic material into cells and aims to create products that can treat various diseases, including cancer and genetic disorders.
What is Precigen's approach to personalized medicine?
Precigen is committed to advancing personalized medicine by developing therapies tailored to the individual characteristics of patients and their diseases. This approach aims to enhance treatment efficacy and minimize side effects, ensuring more successful outcomes.
What is Precigen's mission?
Precigen's mission is to revolutionize the treatment of diseases through innovative gene and cell therapies. The company aims to provide effective and safe solutions that address significant therapeutic challenges and improve the quality of life for patients.
What is the significance of gene therapy in modern medicine?
Gene therapy is significant in modern medicine as it offers the potential to treat and even cure diseases by addressing their root causes. By directly modifying genes, it can lead to more effective treatments for conditions that previously had limited or no options, particularly in rare genetic and chronic diseases.
What is the UltraPorator technology?
The UltraPorator is a proprietary electroporation technology developed by Precigen. It enables the delivery of large DNA plasmids into cells, facilitating the development of gene and cell therapies by enhancing the efficiency of gene transfer into target cells.
What kind of therapies does Precigen focus on?
Precigen focuses on gene therapies and engineered cell therapies. These therapies aim to modify or correct genetic information in order to treat or prevent diseases, particularly in oncology, where they target cancer cells more effectively.
What partnerships does Precigen have?
Precigen has established various strategic partnerships and collaborations with other biotech companies, research institutions, and academic organizations. These partnerships enhance its research capabilities and help expedite the development of new therapies.
What type of diseases does Precigen target?
Precigen targets a variety of diseases with a focus on oncology and genetic disorders. The company’s therapies are designed to tackle complex diseases that currently have limited treatment options, thereby addressing significant unmet medical needs.
When was Precigen, Inc. founded?
Precigen, Inc. was founded in 1995. Over the years, the company has evolved its focus and technology, spearheading advancements in gene therapy and immunotherapy, with a strong commitment to scientific research and development.
Where is Precigen, Inc. headquartered?
Precigen, Inc. is headquartered in Germantown, Maryland. This strategic location allows the company to collaborate closely with other biotechnology firms, research institutions, and regulatory bodies, fostering innovation and growth.
Who leads Precigen, Inc.?
Precigen, Inc. is led by a team of experienced professionals in the biotechnology field. The leadership team includes experts in drug development, operations, and corporate management, aiming to drive the company's vision and mission forward.
What is the current price of Precigen, Inc. - Common Stock?
The current price of Precigen, Inc. - Common Stock is 1.460
When was Precigen, Inc. - Common Stock last traded?
The last trade of Precigen, Inc. - Common Stock was at 2:12 pm EDT on April 2nd, 2025
What is the market capitalization of Precigen, Inc. - Common Stock?
The market capitalization of Precigen, Inc. - Common Stock is 368.53M
How many shares of Precigen, Inc. - Common Stock are outstanding?
Precigen, Inc. - Common Stock has 252.42M shares outstanding.